443 related articles for article (PubMed ID: 16650723)
1. Pharmacotherapy of obsessive-compulsive disorder and obsessive-compulsive spectrum disorders.
Denys D
Psychiatr Clin North Am; 2006 Jun; 29(2):553-84, xi. PubMed ID: 16650723
[TBL] [Abstract][Full Text] [Related]
2. Issues in the pharmacological treatment of obsessive-compulsive disorder.
Math SB; Janardhan Reddy YC
Int J Clin Pract; 2007 Jul; 61(7):1188-97. PubMed ID: 17511795
[TBL] [Abstract][Full Text] [Related]
3. On the pharmacotherapy of obsessive-compulsive disorder: is a consensus possible?
Todorov C; Freeston MH; Borgeat F
Can J Psychiatry; 2000 Apr; 45(3):257-62. PubMed ID: 10779882
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic management of obsessive-compulsive disorder.
Jackson CW; Morton WA; Lydiard RB
South Med J; 1994 Mar; 87(3):310-21. PubMed ID: 8134850
[TBL] [Abstract][Full Text] [Related]
5. Fluvoxamine in the treatment of obsessive-compulsive disorder and related conditions.
Goodman WK; Ward H; Kablinger A; Murphy T
J Clin Psychiatry; 1997; 58 Suppl 5():32-49. PubMed ID: 9184625
[TBL] [Abstract][Full Text] [Related]
6. Pharmacotherapy of obsessive compulsive disorder.
Goodman WK; McDougle CJ; Price LH
J Clin Psychiatry; 1992 Apr; 53 Suppl():29-37. PubMed ID: 1532962
[TBL] [Abstract][Full Text] [Related]
7. Addition of cognitive-behavioral therapy for nonresponders to medication for obsessive-compulsive disorder: a naturalistic study.
Tundo A; Salvati L; Busto G; Di Spigno D; Falcini R
J Clin Psychiatry; 2007 Oct; 68(10):1552-6. PubMed ID: 17960971
[TBL] [Abstract][Full Text] [Related]
8. A review of pharmacologic treatments for obsessive-compulsive disorder.
Kaplan A; Hollander E
Psychiatr Serv; 2003 Aug; 54(8):1111-8. PubMed ID: 12883138
[TBL] [Abstract][Full Text] [Related]
9. The pharmacotherapy of obsessive-compulsive disorder.
McDougle CJ; Goodman WK; Price LH
Pharmacopsychiatry; 1993 May; 26 Suppl 1():24-9. PubMed ID: 8378419
[TBL] [Abstract][Full Text] [Related]
10. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
Pigott TA; Seay SM
J Clin Psychiatry; 1999 Feb; 60(2):101-6. PubMed ID: 10084636
[TBL] [Abstract][Full Text] [Related]
11. Neurobiology and clinical pharmacology of obsessive-compulsive disorder.
Micallef J; Blin O
Clin Neuropharmacol; 2001; 24(4):191-207. PubMed ID: 11479390
[TBL] [Abstract][Full Text] [Related]
12. [Obsessive-compulsive disorder, frontostriatal system and the effect of the serotonergic system].
Baving L; Schmidt MH
Z Kinder Jugendpsychiatr Psychother; 2000 Feb; 28(1):35-44. PubMed ID: 10746297
[TBL] [Abstract][Full Text] [Related]
13. A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder.
Simpson HB; Foa EB; Liebowitz MR; Ledley DR; Huppert JD; Cahill S; Vermes D; Schmidt AB; Hembree E; Franklin M; Campeas R; Hahn CG; Petkova E
Am J Psychiatry; 2008 May; 165(5):621-30. PubMed ID: 18316422
[TBL] [Abstract][Full Text] [Related]
14. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
[TBL] [Abstract][Full Text] [Related]
15. A Systematic Review of Evidence-based Treatment Strategies for Obsessive- compulsive Disorder Resistant to first-line Pharmacotherapy.
Albert U; Marazziti D; Di Salvo G; Solia F; Rosso G; Maina G
Curr Med Chem; 2018; 25(41):5647-5661. PubMed ID: 29278206
[TBL] [Abstract][Full Text] [Related]
16. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.
Simpson HB; Foa EB; Liebowitz MR; Huppert JD; Cahill S; Maher MJ; McLean CP; Bender J; Marcus SM; Williams MT; Weaver J; Vermes D; Van Meter PE; Rodriguez CI; Powers M; Pinto A; Imms P; Hahn CG; Campeas R
JAMA Psychiatry; 2013 Nov; 70(11):1190-9. PubMed ID: 24026523
[TBL] [Abstract][Full Text] [Related]
17. Pharmacotherapy of primary obsessive-compulsive disorder: review of the literature.
Ellingrod VL
Pharmacotherapy; 1998; 18(5):936-60. PubMed ID: 9758307
[TBL] [Abstract][Full Text] [Related]
18. Behavioral therapy and serotonin reuptake inhibitor pharmacotherapy in the treatment of obsessive-compulsive disorder: a systematic review and meta-analysis of head-to-head randomized controlled trials.
Romanelli RJ; Wu FM; Gamba R; Mojtabai R; Segal JB
Depress Anxiety; 2014 Aug; 31(8):641-52. PubMed ID: 24390912
[TBL] [Abstract][Full Text] [Related]
19. Pharmacotherapy for obsessive compulsive disorder in clinical practice - Data of 842 inpatients from the International AMSP Project between 1994 and 2012.
Poppe C; Müller ST; Greil W; Walder A; Grohmann R; Stübner S
J Affect Disord; 2016 Aug; 200():89-96. PubMed ID: 27130958
[TBL] [Abstract][Full Text] [Related]
20. No effect of adding brief dynamic therapy to pharmacotherapy in the treatment of obsessive-compulsive disorder with concurrent major depression.
Maina G; Rosso G; Rigardetto S; Chiadò Piat S; Bogetto F
Psychother Psychosom; 2010; 79(5):295-302. PubMed ID: 20616624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
